Loading clinical trials...
Loading clinical trials...
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo
Conditions
Interventions
MK-6194
Placebo
Locations
68
United States
Cahaba Dermatology & Skin Health Center ( Site 0127)
Birmingham, Alabama, United States
Burke Pharmaceutical Research ( Site 0124)
Hot Springs, Arkansas, United States
The Vitiligo & Pigmentation Institute of Southern California ( Site 0115)
Los Angeles, California, United States
Indiana University Health University Hospital-Indiana University School of Medicine, Department of (
Indianapolis, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC ( Site 0106)
Indianapolis, Indiana, United States
Metro Boston Clinical Partners ( Site 0110)
Brighton, Massachusetts, United States
Start Date
November 27, 2023
Primary Completion Date
March 20, 2025
Completion Date
July 30, 2025
Last Updated
March 17, 2026
NCT07431177
NCT06991972
NCT06511739
NCT06493578
NCT07058051
NCT04052425
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions